Log in or Sign up for Free to view tailored content for your specialty!
Liver/Biliary Disorders News
European Commission approves Livmarli for patients with Alagille syndrome
Mirum Pharmaceuticals announced the European Commission has approved Livmarli for the treatment of cholestatic pruritis in patients with Alagille syndrome.
Linerixibat may relieve itch in primary biliary cholangitis-associated pruritus
Linerixibat induced a dose-dependent reduction in itch among patients with primary biliary cholangitis-associated pruritus, according to results published in Clinical Gastroenterology and Hepatology.
Log in or Sign up for Free to view tailored content for your specialty!
Risk stratification may improve NAFLD intervention in obese, overweight populations
Results from a meta-analysis underscored the need to improve understanding of nonalcoholic fatty liver disease burden and management in at-risk individuals who are overweight and obese.
D-LIVR topline results: Lonafarnib all-oral, combination regimens boost response in HDV
Topline findings from the phase 3 D-LIVR trial showed that lonafarnib — boosted with ritonavir and in combination with peginterferon alfa — improved responses in patients with chronic hepatitis D virus, Eiger BioPharmaceuticals announced.
NAFLD ‘not fit for purpose’: Experts debate impact of changing name vs. definition
WASHINGTON — The term ‘non-alcoholic fatty liver disease’ no longer reflects current knowledge of the disease and should be changed, members of the NAFLD Nomenclature steering committee noted during The Liver Meeting.
Hepatologists’ role in HCV care, elimination ‘remains one of advocacy’
WASHINGTON — A leading expert in hepatology called for fellow specialists to embrace a role of education, advocacy and support as part of a proposed national hepatitis C virus elimination program presented during The Liver Meeting.
Vosevi effective rescue therapy in patients with chronic HCV after DAA treatment failure
WASHINGTON — Vosevi, a triple-combination therapy for chronic hepatitis C virus infection, was effective when used as a rescue treatment in patients who did not achieve sustained virologic response with direct-acting antiviral agents.
The Liver Meeting: Hepatitis in children, NASH, ‘alarming’ disparities in mortality
The Liver Meeting 2022 delivered the latest research and developments on a variety of topics, including acute hepatitis in children, treatment for hepatitis-related cirrhosis and liver disease mortality during the COVID-19 pandemic.
Bariatric surgery lowers risk for any CV outcome among adults with severe obesity, NAFLD
Adults with nonalcoholic fatty liver disease and severe obesity have a lower risk for cardiovascular disease if they undergo bariatric surgery vs. those who do not have surgery, according to study findings published in JAMA Network Open.
Obesity predicts liver disease for children with type 1 diabetes
Clinical and imaging findings of children with type 1 diabetes and obesity were similar to those for children without diabetes with similar degrees of obesity, according study results published in Journal of Diabetes and its Complications.
-
Headline News
‘We have a home’: Physician aims to create network of women allergists
November 14, 20245 min read -
Headline News
Diversified portfolios allow for ‘smoother ride’
November 14, 20243 min read -
Headline News
Predelivery concussion linked to increased risk for severe maternal mental illness
November 12, 20242 min read
-
Headline News
‘We have a home’: Physician aims to create network of women allergists
November 14, 20245 min read -
Headline News
Diversified portfolios allow for ‘smoother ride’
November 14, 20243 min read -
Headline News
Predelivery concussion linked to increased risk for severe maternal mental illness
November 12, 20242 min read